One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
An Approach to Examining Tightly Coiled Hair Among Patients With Hair Loss in Race-Discordant Patient-Physician Interactions
Ciara Grayson, MS; Candrice Heath, MD
doi : 10.1001/jamadermatol.2021.0338
JAMA Dermatol. 2021;157(5):505-506
JAMA Dermatology—The Year in Review, 2020
Kanade Shinkai, MD, PhD
doi : 10.1001/jamadermatol.2021.0275
JAMA Dermatol. 2021;157(5):507-509
The Important Role of Dermatologists in Public Education on Sunscreens
Tasneem F. Mohammad, MD; Henry W. Lim, MD
doi : 10.1001/jamadermatol.2020.5393
JAMA Dermatol. 2021;157(5):509-511
Early Detection of MelanomaRethinking the Outcomes That Matter
Laura K. Ferris, MD, PhD
doi : 10.1001/jamadermatol.2020.5650
JAMA Dermatol. 2021;157(5):511-513
Mohs Micrographic Surgery for Melanoma—Do Outcomes Vary Among Treatment Facilities?
Christopher J. Miller, MD; Christopher K. Bichakjian, MD
doi : 10.1001/jamadermatol.2021.0022
JAMA Dermatol. 2021;157(5):513-515
Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance
Pascale Guitera, MD, PhD; Scott W. Menzies, MB, BS, PhD; Elliot Coates, MB, BS; et al.
doi : 10.1001/jamadermatol.2020.5651
JAMA Dermatol. 2021;157(5):521-530
Importance A previous single-center study observed fewer excisions, lower health care costs, thinner melanomas, and better quality of life when surveillance of high-risk patients was conducted in a melanoma dermatology clinic with a structured surveillance protocol involving full-body examinations every 6 months aided by total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI).
Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma
Shayan Cheraghlou, MD; Sean R. Christensen, MD, PhD; David J. Leffell, MD; et al.
doi : 10.1001/jamadermatol.2021.0023
JAMA Dermatol. 2021;157(5):531-539
Importance Early-stage melanoma, among the most common cancers in the US, is typically treated with wide local excision. However, recent advances in immunohistochemistry have led to an increasing number of these cases being excised via Mohs micrographic surgery (MMS). Although studies of resections for other cancers have reported that facility-level factors are associated with patient outcomes, it is not yet established how these factors may affect outcomes for patients treated with Mohs micrographic surgery.
Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma
Neal Andruska, MD, PhD; Benjamin W. Fischer-Valuck, MD; Lily Mahapatra, MD, PhD; et al.
doi : 10.1001/jamadermatol.2021.0247
JAMA Dermatol. 2021;157(5):540-548
Importance Current recommendations regarding the size of local excision (LE) margins for Merkel cell carcinoma (MCC) have not been well established.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and MelanomaA Systematic Review and Meta-analysis
Megan Lam, BSc; Jie Wei Zhu, BHSc; Mina Tadrous, PharmD, PhD; et al.
doi : 10.1001/jamadermatol.2021.0345
JAMA Dermatol. 2021;157(5):549-558
Importance Topical calcineurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis. In 2006, the US Food and Drug Administration issued a black box warning against TCI use, citing data from case reports and animal studies indicating a potential risk of cancer.
Ten-Year Follow-up of Persons With Sun-Damaged Skin Associated With Subsequent Development of Cutaneous Squamous Cell Carcinoma
Shabnam Madani, MD; Sangeeta Marwaha, MD; Jennifer R. Dusendang, MPH; et al.
doi : 10.1001/jamadermatol.2021.0372
JAMA Dermatol. 2021;157(5):559-565
Importance Risk of cutaneous squamous cell carcinoma (cSCC) after the diagnosis of actinic keratosis (AK) has not been studied during long follow-up periods.
Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma
Esteban Fern?ndez Faith, MD; Sonal Shah, MD; Patricia M. Witman, MD; et al.
doi : 10.1001/jamadermatol.2021.0469
JAMA Dermatol. 2021;157(5):566-572
Importance Ulceration is a common complication of infantile hemangioma (IH), which leads to substantial morbidity. Ulceration in IH has not been systematically studied since the advent of ?-blocker therapy for IH.
Perceived Usefulness and Recall of Sunscreen Label Information by Consumers
Calvin P. Tribby, PhD; Anne K. Julian, PhD; Frank M. Perna, EdD, PhD
doi : 10.1001/jamadermatol.2020.5394
JAMA Dermatol. 2021;157(5):573-576
Importance In February 2019, the US Food and Drug Administration issued a proposed rule (84 FR 6204), an amendment to the Sunscreen Innovation Act of 2014, that would require listing active ingredients on the principal display panel of sunscreens to allow consumers to “more readily compare products and either select or avoid a given product accordingly.”
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer
Leah L. Thompson, BA; Nira A. Krasnow, BS; Michael S. Chang, BA; et al.
doi : 10.1001/jamadermatol.2021.0326
JAMA Dermatol. 2021;157(5):577-582
Importance Cutaneous immune-related adverse events (cirAEs) are some of the earliest toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early indicator of robust inflammatory response, cirAEs may be associated with patterns of immune-mediated toxic effects, but associations between these events and noncutaneous immune-related adverse events (irAEs) remain underexplored.
Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative StageA Randomized Clinical Trial
Fania Z. Mu?oz-Garza, MD; M?nica R?os; Esther Roé-Crespo, MD; et al.
doi : 10.1001/jamadermatol.2021.0596
JAMA Dermatol. 2021;157(5):583-587
Importance Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol. To our knowledge, no studies have determined whether beginning early treatment with timolol for IH is better than in other proliferative stages.
Acute Generalized Exanthematous Pustulosis
Jinwoo Lee, MD, PhD; Alyson Endicott, MD; Kanade Shinkai, MD, PhD
doi : 10.1001/jamadermatol.2020.5187
JAMA Dermatol. 2021;157(5):589
Neonatal Lupus Erythematosus
Jianni Wu, BS; Juliana Berk-Krauss, MD; Sharon A. Glick, MD
doi : 10.1001/jamadermatol.2021.0041
JAMA Dermatol. 2021;157(5):590
Progressive Papular Eruption of the Distal Upper Extremities in a Patient With Asymptomatic Papules
Misty M. Hobbs, MD; Matthew Hall, MD; Jason C. Sluzevich, MD
doi : 10.1001/jamadermatol.2021.0188
JAMA Dermatol. 2021;157(5):591-592
Corrugated Indurated Short Cords on the Neck of a Teenage Girl
An-kang Gu, MD; Jing Li, MD; Li-Tao Zhang, MD, PhD
doi : 10.1001/jamadermatol.2021.0433
JAMA Dermatol. 2021;157(5):593-594
Dermatologist Perceptions of Teledermatology Implementation and Future Use After COVID-19Demographics, Barriers, and Insights
Jonathan Kennedy, BS; Siobhan Arey, MPH, MS, PA-C; Zachary Hopkins, MD; et al.
doi : 10.1001/jamadermatol.2021.0195
JAMA Dermatol. 2021;157(5):595-597
Use of Active Comparator Trials for Topical Medications in Dermatology
John Miller, BA; Sophia Ly, BA; Arash Mostaghimi, MD, MPA, MPH; et al.
doi : 10.1001/jamadermatol.2021.0356
JAMA Dermatol. 2021;157(5):597-599
Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer
Leah L. Thompson, BA; Jaewon Yoon, BA; Nira A. Krasnow, BS; et al.
doi : 10.1001/jamadermatol.2021.0727
JAMA Dermatol. 2021;157(5):599-602
Case of Antiplakin Dermatosis
Naoki Oiso, MD, PhD; Shigeto Yanagihara, MD, PhD; Chiharu Tateishi, MD, PhD; et al.
doi : 10.1001/jamadermatol.2021.0134
JAMA Dermatol. 2021;157(5):602-603
Reactive Infectious Mucocutaneous Eruption Associated With SARS-CoV-2 Infection
Zachary E. Holcomb, MD; Sadaf Hussain, MD; Jennifer T. Huang, MD; et al.
doi : 10.1001/jamadermatol.2021.0385
JAMA Dermatol. 2021;157(5):603-605
JAMA Dermatology Peer Reviewers in 2020
doi : 10.1001/jamadermatol.2021.0128
JAMA Dermatol. 2021;157(5):e210128
